A Phase I Study to Evaluate BFPET as a Potential Myocardial Perfusion Imaging(MPI) Agent for PET

Fluoropharma

Status and phase

Completed

Phase 1

Conditions

Coronary Artery Disease

Treatments

Drug: BFPET

Study type

Interventional

Funder types

Industry

Identifiers

NCT00733460

BFPET P-01

Details and patient eligibility

About

Safety and dosimetry of BFPET™ will be evaluated in healthy volunteers and Coronary Artery Disease (CAD) patients , male or female and of age ranging between 20-80 years old.

Full description

Study Procedures:

Visit 1: Screening - Eligibility determination

Visit 2 (within 14 days post screening): Injection of BFPET™ and PET Imaging

Visit 3 (within 24-48 hours post dose): Follow-up Visit

Enrollment

12 patients

Sex

All

Ages

20 to 80 years old

Volunteers

Accepts Healthy Volunteers

Inclusion and exclusion criteria

NORMAL HEALTHY VOLUNTEERS Inclusion Criteria

Subject must provide written informed consent prior to any study related procedures;
Subject must be ≥ 20 and ≤ 80 years of age;
Subject must have a serum creatinine within the investigational site's normal range.
Subject must have liver function tests < 1.5 times the investigational site's normal range.
Subject must have a hematocrit level within 5% of the investigational site's normal range.

Exclusion Criteria:

Any clinically significant acute or unstable physical or psychological disease based on medical history or screening physical examination;
Any clinically significant abnormality in the screening laboratory tests or ECG;
Any exposure to any investigational drugs within four (4) weeks prior to Visit 1;
Any exposure to investigational radiopharmaceuticals within four (4) weeks prior to the date of Visit 1;
Any new prescription medications within four (4) weeks of Visit 1;
Subject has a Positive (+) Serum Pregnancy Test, or the possibility of pregnancy cannot be ruled out prior to dosing or is breast-feeding. There are standard pregnancy procedures for use of radiopharmaceuticals in research at MGH.
Subject has experienced any allergic reaction to similar radiofluorinated compounds or agents.

CORONARY ARTERY DISEASE (CAD) SUBJECTS

Inclusion Criteria:

Subjects must provide written informed consent prior to any study related procedures;
Subjects must be ≥ 20 and ≤ 80 years of age;
Subjects must have history of CAD documented by an abnormal stress myocardial perfusion imaging (MPI) study and cardiac catheterization within 6 months of the BFPET studyExclusion Criteria

Exclusion Criteria:

Subject has a Positive (+) Serum and/or Urine Pregnancy Test or is lactating, or the possibility of pregnancy cannot be ruled out prior to dosing;
Any clinically significant acute or unstable physical or psychological disease judged by the investigators based on medical history or screening physical examination;
Coronary artery bypass graft (CABG) within 6 months;
Percutaneous coronary intervention (PCI), with stent placement within six months;
Blood pressure over 180/100;
Acute changes in ECG;
Recent (within 3 months) cardiac arrest, unstable angina, myocardial infarction, cerebro-vascular accident (CVA), any general anesthesia procedure, any surgical procedures;
Any implanted pacemaker or defibrillator use within the last three months;
Inability to remain in camera for approximately 60 minutes (Smokers and COPD are included as long as they can breath in PET camera and not taking O2 through nasal canula);
History of Diabetes Mellitus;
Serum creatinine > 2 mg/dL;
All cancer patients;
Body Mass Index (BMI) is over 35;
Any exposure to any investigational drugs or medical device within four (4) weeks prior to imaging study;
Any exposure to radiopharmaceuticals within four (4) weeks prior to the date of imaging study;